Zofia Rogó'

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6481268/publications.pdf

Version: 2024-02-01

331670 395702 1,316 61 21 33 citations h-index g-index papers 63 63 63 1540 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology, 2002, 42, 1024-1030.	4.1	164
2	The behavioural effects of pramipexole, a novel dopamine receptor agonist. European Journal of Pharmacology, 1997, 324, 31-37.	3.5	75
3	Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain. European Journal of Pharmacology, 1998, 351, 31-37.	3.5	71
4	Effect of Antidepressant Drugs in Mice Lacking the Norepinephrine Transporter. Neuropsychopharmacology, 2006, 31, 2424-2432.	5.4	64
5	Antidepressant drugs given repeatedly change the binding of the dopamine D2 receptor agonist, [3H]N-0437, to dopamine D2 receptors in the rat brain. European Journal of Pharmacology, 1996, 304, 49-54.	3.5	46
6	Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacological Reports, 2011, 63, 1547-1552.	3.3	38
7	Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacological Reports, 2013, 65, 1535-1544.	3.3	36
8	Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacological Reports, 2007, 59, 778-84.	3.3	34
9	Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacological Reports, 2006, 58, 493-500.	3.3	30
10	Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacological Reports, 2012, 64, 1391-1399.	3.3	29
11	Fluvoxamine, a new antidepressant drug, fails to show antiserotonin activity. European Journal of Pharmacology, 1982, 81, 287-292.	3.5	27
12	Inhibitory effects of amantadine on the production of pro-inflammatory cytokines by stimulated in vitro human blood. Pharmacological Reports, 2009, 61, 1105-1112.	3.3	27
13	Antidepressant-like effect of PRE-084, a selective ${\dagger}f1$ receptor agonist, in Albino Swiss and C57BL/6J mice. Pharmacological Reports, 2009, 61, 1179-1183.	3.3	27
14	Depressive-like effect of prenatal exposure to DDT involves global DNA hypomethylation and impairment of GPER1/ESR1 protein levels but not ESR2 and AHR/ARNT signaling. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 94-109.	2.5	26
15	Combined treatment with imipramine and metyrapone induces hippocampal and cortical brain-derived neurotrophic factor gene expression in rats. Pharmacological Reports, 2005, 57, 840-4.	3.3	25
16	Neuropharmacological profile of EMD 57445, a if receptor ligand with potential antipsychotic activity. European Journal of Pharmacology, 1996, 315, 235-243.	3.5	23
17	Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice. Pharmacological Reports, 2013, 65, 1401-1406.	3.3	23
18	Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Polish Journal of Pharmacology, 2004, 56, 179-85.	0.3	23

#	Article	IF	CITATIONS
19	Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacological Reports, 2008, 60, 817-26.	3.3	23
20	Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats. Neurotoxicity Research, 2016, 30, 606-619.	2.7	22
21	Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. International Journal of Neuropsychopharmacology, 2006, 9, 297.	2.1	21
22	Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test. Pharmacological Reports, 2009, 61, 1069-1077.	3.3	21
23	Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacological Reports, 2013, 65, 1144-1151.	3.3	21
24	Effect of co-administration of fluoxetine and amantadine on immunoendocrine parameters in rats subjected to a forced swimming test. Pharmacological Reports, 2009, 61, 1050-1060.	3.3	20
25	Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacological Reports, 2012, 64, 1567-1572.	3.3	20
26	Reserpine-induced locomotor stimulation in mice chronically treated with typical and atypical antidepressants. European Journal of Pharmacology, 1983, 87, 469-474.	3. 5	19
27	Stimulatory effect of antidepressant drug pretreatment on progression of B16F10 melanoma in high-active male and female C57BL/6J mice. Journal of Neuroimmunology, 2011, 240-241, 34-44.	2.3	19
28	Alterations in the Antioxidant Enzyme Activities in the Neurodevelopmental Rat Model of Schizophrenia Induced by Glutathione Deficiency during Early Postnatal Life. Antioxidants, 2020, 9, 538.	5.1	19
29	Effect of acute and repeated treatment with mirtazapine on the immunity of noradrenaline transporter knockout C57BL/6J mice. Pharmacology Biochemistry and Behavior, 2006, 85, 813-819.	2.9	17
30	The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats. Pharmacological Reports, 2015, 67, 1183-1187.	3.3	17
31	Repeated co-treatment with antidepressants and risperidone increases BDNF mRNA and protein levels in rats. Pharmacological Reports, 2017, 69, 885-893.	3.3	15
32	Glutathione Deficiency and Alterations in the Sulfur Amino Acid Homeostasis during Early Postnatal Development as Potential Triggering Factors for Schizophrenia-Like Behavior in Adult Rats. Molecules, 2019, 24, 4253.	3.8	15
33	Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. Behavioural Brain Research, 2020, 393, 112769.	2.2	15
34	Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Polish Journal of Pharmacology, 2004, 56, 849-55.	0.3	15
35	Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharmacological Reports, 2009, 61, 1173-1178.	3.3	14
36	Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacological Reports, 2011, 63, 1533-1538.	3.3	14

#	Article	IF	Citations
37	Effects of co-administration of fluoxetine and risperidone on properties of peritoneal and pleural macrophages in rats subjected to the forced swimming test. Pharmacological Reports, 2012, 64, 1368-1380.	3.3	14
38	The effect of combined treatment with escitalopram and risperidone on the MK-801-induced changes in the object recognition test in mice. Pharmacological Reports, 2016, 68, 116-120.	3.3	14
39	Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Sprague–Dawley Rats. International Journal of Molecular Sciences, 2021, 22, 6171.	4.1	13
40	Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacological Reports, 2008, 60, 880-8.	3.3	13
41	The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. Pharmacological Reports, 2018, 70, 1023-1031.	3.3	12
42	Antidepressant-like effect of combined treatment with selective sigma receptor agonists and a 5-HT1A receptor agonist in the forced swimming test in rats. Pharmacological Reports, 2007, 59, 773-7.	3.3	12
43	Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex. Pharmacological Reports, 2010, 62, 1015-1022.	3.3	10
44	Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. Pharmacological Reports, 2019, 71, 768-773.	3.3	10
45	Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Polish Journal of Pharmacology, 2003, 55, 449-54.	0.3	10
46	N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia. International Journal of Molecular Sciences, 2022, 23, 2125.	4.1	10
47	Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. Pharmacological Reports, 2018, 70, 623-630.	3.3	9
48	Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. Polish Journal of Pharmacology, 2004, 56, 735-42.	0.3	9
49	Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. Pharmacological Reports, 2017, 69, 13-21.	3.3	8
50	Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors. Polish Journal of Pharmacology, 2002, 54, 593-603.	0.3	8
51	Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Polish Journal of Pharmacology, 2003, 55, 993-9.	0.3	7
52	Some central effects of impromidine, a potent agonist of histamine H2 receptors. Neuropharmacology, 1980, 19, 947-950.	4.1	6
53	Some behavioural effects of antidepressant drugs are time-dependent. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 373-393.	4.8	6
54	The effect of risperidone on the mirtazapine-induced changes in extracellular monoamines in the rat frontal cortex. Pharmacological Reports, 2014, 66, 984-990.	3.3	5

#	Article	IF	CITATIONS
55	Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Polish Journal of Pharmacology, 2002, 54, 381-9.	0.3	5
56	Effect of repeated co-treatment with imipramine and metyrapone on the behavioral reactivity of the central serotonin, dopamine and alpha 1-adrenergic systems in rats. Pharmacological Reports, 2007, 59, 588-94.	3.3	5
57	Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice. Pharmacological Reports, 2010, 62, 1191-6.	3.3	5
58	Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats. Pharmacological Reports, 2009, 61, 924-929.	3.3	4
59	Stimulatory effect of desipramine on lung metastases of adenocarcinoma MADB 106 in stress highly-sensitive and stress non-reactive rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 279-290.	4.8	3
60	Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague–Dawley rats exposed to glutathione deficit during early postnatal development of the brain. Pharmacological Reports, 2021, 73, 1712-1723.	3.3	3
61	The Effect of Glutathione Deficit During Early Postnatal Brain Development on the Prepulse Inhibition and Monoamine Levels in Brain Structures of Adult Sprague–Dawley Rats. Neurotoxicity Research, 2022, , 1.	2.7	0